Oct. 3 at 1:27 AM
$OBIO Accumulate at/under placement
$2.75, and you (as an investor) should do well (IMO). The SP is trading presently at/near its ATL, consolidating following equity placements.
$112M in equity provided the Company, including
$71M from
$MDT and
$LGND. 137 Global Patents have already been accumulated by the Company, breakthrough device designation conferred which should allow preferential treatment from FDA, Cash runway to H2-2027 and established/known contracts with MDT upon FDA approval. It may take some time (mid-2026); however, the stock has multiplier potential upon successful study results and ultimately FDA approval.
